We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences plc | AQSE:PRM.GB | Aquis Stock Exchange | Ordinary Share | GB0003104196 | Ordinary Shares 1p |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.35 | 2.50 | 4.80 | 3.65 | 3.30 | 3.35 | 0.00 | 11:29:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2022 to Dec 2024
TIDMPRM
RNS Number : 3395B
Proteome Sciences PLC
01 June 2023
1 June 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Repayment of Loan to Vulpes Investment Management Private Limited
The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling GBP824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.
Proteome Sciences plc Dr. Mariola Soehngen, Chief Executive Officer Tel: +44 (0)20 7043 2116 Dr. Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer Allenby Capital Limited (Nominated Adviser & Broker) John Depasquale / Jeremy Porter (Corporate Tel: +44 (0) 20 3328 5656 Finance) Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFIFSTRIILIIV
(END) Dow Jones Newswires
June 01, 2023 04:43 ET (08:43 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
